NMT1

Summary

NMT1 (N-myristoyltransferase 1, HGNC:7857) is a protein-coding gene on chromosome 17q21.31, encoding Glycylpeptide N-tetradecanoyltransferase 1 (P30419). Adds a myristoyl group to the N-terminal glycine residue of certain cellular and viral proteins. It is a selective cancer dependency (DepMap: 67.6% of cell lines).

Myristate, a rare 14-carbon saturated fatty acid, is cotranslationally attached by an amide linkage to the N-terminal glycine residue of cellular and viral proteins with diverse functions. N-myristoyltransferase (NMT; EC 2.3.1.97) catalyzes the transfer of myristate from CoA to proteins. N-myristoylation appears to be irreversible and is required for full expression of the biologic activities of several N-myristoylated proteins, including the alpha subunit of the signal-transducing guanine nucleotide-binding protein (G protein) GO (GNAO1; MIM 139311) (Duronio et al., 1992 [PubMed 1570339]).

Source: NCBI Gene 4836 — RefSeq curated summary.

At a glance

• GWAS associations: 18
• Clinical variants (ClinVar): 43 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• Cancer dependency (DepMap): dependent in 67.6% of screened cell lines
• MANE Select transcript: NM_021079

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7857
Approved symbol	NMT1
Name	N-myristoyltransferase 1
Location	17q21.31
Locus type	gene with protein product
Status	Approved
Aliases	NMT
Ensembl gene	ENSG00000136448
Ensembl biotype	protein_coding
OMIM	160993
Entrez	4836

Gene structure

Transcript identifiers

Ensembl transcripts: 21 — 8 protein_coding, 8 nonsense_mediated_decay, 4 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000258960, ENST00000543908, ENST00000585561, ENST00000587014, ENST00000587120, ENST00000587670, ENST00000588455, ENST00000590114, ENST00000590310, ENST00000591931, ENST00000592654, ENST00000592782, ENST00000676753, ENST00000676828, ENST00000677949, ENST00000678332, ENST00000678576, ENST00000678606, ENST00000678938, ENST00000902321, ENST00000927701

RefSeq mRNA: 1 — MANE Select: NM_021079 NM_021079

CCDS: CCDS11494

Canonical transcript exons

ENST00000258960 — 12 exons

Exon	Start	End
ENSE00001324312	45061317	45061460
ENSE00003482903	45096194	45096285
ENSE00003502831	45081644	45081752
ENSE00003508155	45093685	45093803
ENSE00003530469	45098382	45098552
ENSE00003657919	45097128	45097244
ENSE00003757306	45086508	45086652
ENSE00003889006	45105619	45109016
ENSE00003889170	45102951	45103121
ENSE00003892102	45104859	45104996
ENSE00003894395	45103709	45103876
ENSE00003895401	45099405	45099513

Expression profiles

Bgee: expression breadth ubiquitous, 296 present calls, max score 94.42.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 128.3673 / max 1259.8621, expressed in 1827 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
161230	128.2281	1827
161231	0.0807	61
161225	0.0406	31
161229	0.0179	4

Top tissues by expression

302 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	94.42	gold quality
right adrenal gland	UBERON:0001233	94.34	gold quality
islet of Langerhans	UBERON:0000006	94.30	gold quality
mononuclear cell	CL:0000842	94.28	gold quality
sural nerve	UBERON:0015488	94.27	gold quality
leukocyte	CL:0000738	94.21	gold quality
gastrocnemius	UBERON:0001388	94.09	gold quality
left adrenal gland	UBERON:0001234	93.95	gold quality
right adrenal gland cortex	UBERON:0035827	93.93	gold quality
muscle of leg	UBERON:0001383	93.89	gold quality
calcaneal tendon	UBERON:0003701	93.87	gold quality
left adrenal gland cortex	UBERON:0035825	93.76	gold quality
granulocyte	CL:0000094	93.74	gold quality
adrenal gland	UBERON:0002369	93.50	gold quality
adrenal cortex	UBERON:0001235	93.46	gold quality
right frontal lobe	UBERON:0002810	93.38	gold quality
adrenal tissue	UBERON:0018303	93.31	gold quality
smooth muscle tissue	UBERON:0001135	93.16	gold quality
prefrontal cortex	UBERON:0000451	93.08	gold quality
stromal cell of endometrium	CL:0002255	92.93	gold quality
lower esophagus muscularis layer	UBERON:0035833	92.83	gold quality
lower esophagus	UBERON:0013473	92.82	gold quality
lymph node	UBERON:0000029	92.72	gold quality
right lobe of liver	UBERON:0001114	92.70	gold quality
hindlimb stylopod muscle	UBERON:0004252	92.70	gold quality
thoracic aorta	UBERON:0001515	92.67	gold quality
right coronary artery	UBERON:0001625	92.67	gold quality
descending thoracic aorta	UBERON:0002345	92.67	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	92.66	gold quality
ascending aorta	UBERON:0001496	92.59	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	11.95

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

113 targeting NMT1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-10401-5P	99.99	65.79	948
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-23B-5P	99.98	66.07	587
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-3605-5P	99.96	67.12	932
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-589-3P	99.91	69.62	2088
HSA-MIR-4493	99.90	66.48	977
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-374B-5P	99.90	69.98	2734
HSA-MIR-9902	99.89	69.15	2250
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-30D-3P	99.87	69.92	2917
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30E-3P	99.87	69.68	2942
HSA-MIR-369-3P	99.85	70.52	2264
HSA-MIR-5003-3P	99.85	69.29	2517
HSA-MIR-4447	99.85	67.81	2900

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 67.6% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 17)

• In this study, we found decreases in the mRNA levels of human NMT isoforms and the NMT activities in the course of HIV-1 infection in the human T-cell line (PMID:12220649)
• role of HSC70 in the regulation of NMT (PMID:15156568)
• NMT1 and NMT2 have only partially overlapping functions; NMT1 is critical for tumor cell proliferation (PMID:16123142)
• Elevated N-myristoyltransferase activity is associated with oral squamous cell carcinoma (PMID:17549352)
• N-myristoyltransferase may have a role in progression of colonic neoplasms (PMID:18021392)
• Nef is preferentially myristoylated by NMT2, suggesting that selective inhibition of NMT2 may provide a novel means of blocking HIV virulence. (PMID:18089753)
• These results strongly suggest that HIV-1 production is specifically associated with hNMT1, particularly hNMT1(L), but not with hNMT2 in vivo, contributing to the understanding of a step in HIV-1 replication. (PMID:18248763)
• we propose a model of the Nef:NMT complex in which only the myristoyl moiety holds the two proteins together in complex and speculate that perhaps NMT chaperones Nef to the membrane and thereby protects the myristic acid group from the cytosol (PMID:21449607)
• findings suggest that both NMT1 and hnRNP A2/B1 take part in the regulation of HIV-1 RNA expression through their mutual opposite effects on the viral RNA expression in HIV-1-producing cells (PMID:26074144)
• These observations point at a previously unrecognized contribution of calnexin to the retention of NMT1 at the ER membrane. (PMID:26603938)
• Genetic and pharmacologic evidence that inhibiting the N-myristoyltransferase NMT1 suppresses cell-cycle progression, proliferation, and malignant growth of prostate cancer cells. (PMID:29038344)
• mTOR, a downstream target of PKB/Akt, regulates NMT1 in ER positive breast cancer cells (MCF7 cells). NMT1 increased with rapamycin treatment over the period of time with a concomitant decrease in mTOR phosphorylation. (PMID:30154572)
• inhibition of NMT1 caused degraded proteins increase and ER stress, which cross-talked with mitochondria to produce more ROS. And both of oxidative stress and ER stress could activate JNK pathway, leading to autophagy which abrogated breast cancer progression especially triple-negative breast cancer (TNBC). (PMID:30446635)
• Data showed that rheumatoid arthritis (RA) T cells had a defect in type I N-myristoyltransferase (NMT1) function, which prevented AMP-activated protein kinase (AMPK) activation. (PMID:30718913)
• N-myristoyltransferase-1 deficiency blocks myristoylation of LAMTOR1 and inhibits bladder cancer progression. (PMID:34999170)
• N-mytistoyltransferase 1 and 2 are potential tumor suppressors and novel targets of miR-182 in human non-small cell lung carcinomas. (PMID:35930829)
• SPI1 Mediates N-Myristoyltransferase 1 to Advance Gastric Cancer Progression via PI3K/AKT/mTOR Pathway. (PMID:36967718)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	nmt1a	ENSDARG00000052966
danio_rerio	nmt1b	ENSDARG00000057206
mus_musculus	Nmt1	ENSMUSG00000020936
rattus_norvegicus	Nmt1	ENSRNOG00000002989
drosophila_melanogaster	Nmt	FBGN0020392
caenorhabditis_elegans		WBGENE00020549

Paralogs (1): NMT2 (ENSG00000152465)

Protein

Protein identifiers

Glycylpeptide N-tetradecanoyltransferase 1 — P30419 (reviewed: P30419)

Alternative names: Myristoyl-CoA:protein N-myristoyltransferase 1, Peptide N-myristoyltransferase 1, Protein-lysine myristoyltransferase NMT1

All UniProt accessions (11): A0A7I2V3M5, A0A7I2V3U5, A0A7I2V3X4, A0A7I2V4Y5, A0A7I2V539, A0A7I2V5J6, A0A7I2V5M6, B7Z8J4, P30419, K7EN42, K7EN82

UniProt curated annotations — full annotation on UniProt →

Function. Adds a myristoyl group to the N-terminal glycine residue of certain cellular and viral proteins. Also able to mediate N-terminal lysine myristoylation of proteins: catalyzes myristoylation of ARF6 on both ‘Gly-2’ and ‘Lys-3’. Lysine myristoylation is required to maintain ARF6 on membranes during the GTPase cycle.

Subcellular location. Cytoplasm. Cytosol. Membrane.

Tissue specificity. Heart, gut, kidney, liver and placenta.

Similarity. Belongs to the NMT family.

Isoforms (2)

UniProt ID	Names	Canonical?
P30419-1	Long	yes
P30419-2	Short

RefSeq proteins (1): NP_066565* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000903	NMT	Family
IPR016181	Acyl_CoA_acyltransferase	Homologous_superfamily
IPR022676	NMT_N	Domain
IPR022677	NMT_C	Domain
IPR022678	NMT_CS	Conserved_site

Pfam: PF01233, PF02799

Enzyme classification (BRENDA):

• EC 2.3.1.97 — glycylpeptide N-tetradecanoyltransferase (BRENDA: 25 organisms, 184 substrates, 380 inhibitors, 83 Km, 22 kcat entries)

Substrate kinetics (BRENDA)

36 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
MYRISTOYL-COA	—	23
CAMP-DEPENDENT PROTEIN KINASE-DERIVED PEPTIDE	0.1–0.2	5
GLY-ASN-ALA-ALA-SER-ALA-ARG-ARG	0.0001–0.006	5
GLY-ASN-ALA-ALA-ALA-ALA-ARG-ARG	0.016–0.6	4
P60SRC-DERIVED PEPTIDE	0.016–0.06	4
CAP5.5 PEPTIDE	0.012–0.25	2
HIV-1 NEGATIVE REGULATORY FACTOR	0.0144–0.0257	2
HIV1 GAG PROTEIN N-TERMINAL PEPTIDE	0.196–0.33	2
HIV1 NEF PROTEIN N-TERMINAL PEPTIDE	0.0015–0.011	2
PEPTIDE HS PP60SRC(2-9)	0.0028	2
11-(ETHYLTHIO)-UNDECANOYL-COA	0.0007	1
ARABIDOPSIS THALIANA PROTEIN CDPK6-DERIVED PEPTI	0.0205	1
ARF PEPTIDE	0.0175	1
CAP5.5	0.022	1
GCGGSKVK	0.0113	1

Catalyzed reactions (Rhea), 2 shown:

• N-terminal glycyl-[protein] + tetradecanoyl-CoA = N-tetradecanoylglycyl-[protein] + CoA + H(+) (RHEA:15521)
• N-terminal glycyl-L-lysyl-[protein] + tetradecanoyl-CoA = N-terminal glycyl-(N(6)-tetradecanoyl)-L-lysyl-[protein] + CoA + H(+) (RHEA:70671)

UniProt features (65 total): strand 23, helix 15, binding site 11, mutagenesis site 4, turn 4, modified residue 3, chain 1, region of interest 1, splice variant 1, sequence variant 1, compositionally biased region 1

Structure

Experimental structures (PDB)

52 structures, top 30 by resolution.

PDB	Method	Resolution (Å)
5O6H	X-RAY DIFFRACTION	1.29
3IU1	X-RAY DIFFRACTION	1.42
5O6J	X-RAY DIFFRACTION	1.45
7OWM	X-RAY DIFFRACTION	1.5
3JTK	X-RAY DIFFRACTION	1.61
4C2Y	X-RAY DIFFRACTION	1.64
7OWO	X-RAY DIFFRACTION	1.7
3IU2	X-RAY DIFFRACTION	1.73
8Q3S	X-RAY DIFFRACTION	1.78
3IWE	X-RAY DIFFRACTION	1.79
7OWP	X-RAY DIFFRACTION	1.81
5O9U	X-RAY DIFFRACTION	1.85
6SK8	X-RAY DIFFRACTION	1.87
5MU6	X-RAY DIFFRACTION	1.88
8Q2Z	X-RAY DIFFRACTION	1.88
6FZ5	X-RAY DIFFRACTION	1.89
8Q23	X-RAY DIFFRACTION	1.9
8Q24	X-RAY DIFFRACTION	1.9
8Q26	X-RAY DIFFRACTION	1.9
6SK2	X-RAY DIFFRACTION	1.9
6F56	X-RAY DIFFRACTION	1.94
8Q3T	X-RAY DIFFRACTION	1.96
6SJZ	X-RAY DIFFRACTION	2
6FZ3	X-RAY DIFFRACTION	2
6FZ2	X-RAY DIFFRACTION	2.05
7RK3	X-RAY DIFFRACTION	2.05
4C2Z	X-RAY DIFFRACTION	2.08
7OWU	X-RAY DIFFRACTION	2.08
6EHJ	X-RAY DIFFRACTION	2.1
7OWN	X-RAY DIFFRACTION	2.1

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P30419-F1	84.05	0.71

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (11): 256; 258; 259; 260; 118; 119; 120; 247; 248; 249; 250

Post-translational modifications (3): 31, 47, 83

Mutagenesis-validated functional residues (4):

Position	Phenotype
180	abolished glycine- and lysine-myristoyltransferase activities.
181	reduced glycine n-myristoyltransferase activity.
192	reduced glycine n-myristoyltransferase activity.
492	reduced activity.

Function

Pathways and Gene Ontology

Reactome pathways

5 pathways

ID	Pathway
R-HSA-162599	Late Phase of HIV Life Cycle
R-HSA-203615	eNOS activation
R-HSA-2514859	Inactivation, recovery and regulation of the phototransduction cascade
R-HSA-75108	Activation, myristolyation of BID and translocation to mitochondria
R-HSA-9918432	Maturation of DENV proteins

MSigDB gene sets: 266 (showing top): GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_DN, TSENG_IRS1_TARGETS_UP, MORF_MSH3, SWEET_KRAS_ONCOGENIC_SIGNATURE, GOBP_LIPOPROTEIN_METABOLIC_PROCESS, BECKER_TAMOXIFEN_RESISTANCE_UP, GOBP_CELLULAR_RESPONSE_TO_LIGHT_STIMULUS, MORF_BRCA1, MORF_ATRX, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN, TATTATA_MIR374, GOBP_PHOTOTRANSDUCTION, KYNG_DNA_DAMAGE_DN

GO Biological Process (10): in utero embryonic development (GO:0001701), N-terminal peptidyl-glycine N-myristoylation (GO:0018008), regulation of opsin-mediated signaling pathway (GO:0022400), ketone metabolic process (GO:0042180), protein localization to membrane (GO:0072657), positive regulation of protein localization to mitochondrion (GO:1903749), N-terminal protein myristoylation (GO:0006499), cellular response to nutrient levels (GO:0031669), positive regulation of protein localization to lysosome (GO:0150032), positive regulation of TORC1 signaling (GO:1904263)

GO Molecular Function (6): glycylpeptide N-tetradecanoyltransferase activity (GO:0004379), peptidyl-lysine N6-myristoyltransferase activity (GO:0018030), myristoyltransferase activity (GO:0019107), protein binding (GO:0005515), transferase activity (GO:0016740), acyltransferase activity (GO:0016746)

GO Cellular Component (4): cytoplasm (GO:0005737), cytosol (GO:0005829), plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
HIV Life Cycle	1
Metabolism of nitric oxide: NOS3 activation and regulation	1
The phototransduction cascade	1
Intrinsic Pathway for Apoptosis	1
Dengue Virus Genome Translation and Replication	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
positive regulation of protein localization	2
myristoyltransferase activity	2
chordate embryonic development	1
N-terminal protein myristoylation	1
peptidyl-glycine modification	1
regulation of G protein-coupled receptor signaling pathway	1
G protein-coupled opsin signaling pathway	1
regulation of response to external stimulus	1
metabolic process	1
intracellular protein localization	1
localization within membrane	1
protein localization to mitochondrion	1
regulation of protein localization to mitochondrion	1
N-terminal protein lipidation	1
protein myristoylation	1
response to nutrient levels	1
cellular response to stimulus	1
protein localization to lysosome	1
regulation of protein localization to lysosome	1
positive regulation of TOR signaling	1
TORC1 signaling	1
regulation of TORC1 signaling	1
catalytic activity, acting on a protein	1
acyltransferase activity, transferring groups other than amino-acyl groups	1
binding	1
catalytic activity	1
transferase activity	1
intracellular anatomical structure	1
cytoplasm	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

1588 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NMT1	SRC	P12931	619
NMT1	GNAO1	P09471	601
NMT1	DBI	P07108	554
NMT1	UGP2	Q16851	545
NMT1	DCAKD	Q8WVC6	533
NMT1	ACBD6	Q9BR61	502
NMT1	ARF1	P10947	500
NMT1	POTEI	P0CG38	490
NMT1	PKNOX1	P55347	464
NMT1	POTEJ	P0CG39	456
NMT1	LGI1	O95970	446
NMT1	METAP2	P50579	435
NMT1	GPR132	Q9UNW8	434
NMT1	UNC119	Q13432	410
NMT1	XPO7	Q9UIA9	406

IntAct

98 interactions, top by confidence:

A	B	Type	Score
ACBD6	NMT2	psi-mi:“MI:0914”(association)	0.870
NMT1	ACBD6	psi-mi:“MI:0915”(physical association)	0.820
nef	ACOT8	psi-mi:“MI:0914”(association)	0.710
LRATD2	NMT2	psi-mi:“MI:0914”(association)	0.640
MGST3	GAPDHS	psi-mi:“MI:0914”(association)	0.530
NCS1	NMT2	psi-mi:“MI:0914”(association)	0.530
MARCKSL1	NMT2	psi-mi:“MI:0914”(association)	0.530
CIMAP1D	NMT2	psi-mi:“MI:0914”(association)	0.530
TGFB1	NMT2	psi-mi:“MI:0914”(association)	0.530
ANGPTL4	NMT2	psi-mi:“MI:0914”(association)	0.530
MEAK7	NMT2	psi-mi:“MI:0914”(association)	0.530
ANGPTL7	TCP1	psi-mi:“MI:0914”(association)	0.530
FBXO17	NMT2	psi-mi:“MI:0914”(association)	0.530
CASP3	NMT1	psi-mi:“MI:0570”(protein cleavage)	0.440
CASP8	NMT1	psi-mi:“MI:0570”(protein cleavage)	0.440
CAPN2	NMT1	psi-mi:“MI:0915”(physical association)	0.400
TP53	NMT1	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (207): NMT1 (Affinity Capture-RNA), CAPN1 (Affinity Capture-Western), TP53 (Affinity Capture-Western), NMT1 (Affinity Capture-MS), NMT1 (Affinity Capture-MS), NMT1 (Affinity Capture-MS), NMT1 (Affinity Capture-MS), NMT1 (Affinity Capture-MS), NMT1 (Affinity Capture-MS), NMT1 (Affinity Capture-MS), NMT1 (Affinity Capture-MS), NMT1 (Affinity Capture-MS), NMT1 (Affinity Capture-MS), NMT1 (Affinity Capture-MS), ACSL4 (Co-fractionation)

ESM2 similar proteins: A2VE39, A4IFJ5, A4IHT9, A8K855, B1WAZ6, D2HRF1, O00763, O02697, O60551, O70310, O77793, P19447, P30419, P31717, P35574, P47712, P47713, P48736, P49147, P50392, P50393, Q0E908, Q2PQH8, Q2TBU5, Q4R6Y8, Q5R8A5, Q5R981, Q5U2Z5, Q5ZJT0, Q641K1, Q66HX8, Q6DD21, Q7K556, Q7T0T9, Q7XQT2, Q80YD1, Q811C2, Q8C5P5, Q8IYB8, Q8K1Q0

Diamond homologs: A7YT82, O43010, O60551, O61613, O70310, O70311, O74234, P0CP20, P0CP21, P14743, P30418, P30419, P31717, P34763, P34809, P46548, Q4I061, Q4PB56, Q553B6, Q5RAF3, Q6BJF4, Q6C7G2, Q6CMK4, Q75EK2, Q7S3C8, Q8ILW6, Q8K1Q0, Q8TFN1, Q94L32, Q9LTR9, Q9N181, Q9U419, Q9UVX3, Q9EMI7

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
FYN	unknown	NMT1	phosphorylation
LYN	unknown	NMT1	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 112 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
SARS-CoV-2 modulates host translation machinery	5	16.7×	2e-03
Influenza Infection	5	13.1×	3e-03
Signaling by ALK fusions and activated point mutants	5	11.2×	3e-03
SARS-CoV-2-host interactions	6	10.7×	2e-03
Anchoring of the basal body to the plasma membrane	5	8.4×	7e-03
SARS-CoV-2 Infection	6	7.2×	5e-03
Signaling by Interleukins	6	5.8×	1e-02
Viral Infection Pathways	9	4.1×	7e-03

GO biological processes:

GO term	Partners	Fold	FDR
cytoplasmic translation	6	11.9×	6e-03
cilium assembly	11	8.7×	5e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

43 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	29
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

4261 predictions. Top by Δscore:

Variant	Effect	Δscore
17:44960363:CGCAC:C	acceptor_gain	1.0000
17:44960364:GCAC:G	acceptor_gain	1.0000
17:44960365:CAC:C	acceptor_gain	1.0000
17:44960365:CACC:C	acceptor_gain	1.0000
17:44960366:AC:A	acceptor_gain	1.0000
17:44960367:CC:C	acceptor_gain	1.0000
17:44960367:CCTG:C	acceptor_loss	1.0000
17:44960368:CTGCG:C	acceptor_loss	1.0000
17:44960369:T:C	acceptor_loss	1.0000
17:44960374:G:GC	acceptor_gain	1.0000
17:44960382:C:CT	acceptor_gain	1.0000
17:44960385:G:T	acceptor_gain	1.0000
17:45024722:TCG:T	acceptor_gain	1.0000
17:45024723:CG:C	acceptor_gain	1.0000
17:45024723:CGC:C	acceptor_gain	1.0000
17:45030444:T:C	acceptor_gain	1.0000
17:45034185:A:AC	donor_gain	1.0000
17:45034185:AC:A	donor_gain	1.0000
17:45034185:ACC:A	donor_gain	1.0000
17:45034185:ACCC:A	donor_gain	1.0000
17:45034186:C:CC	donor_gain	1.0000
17:45034186:CC:C	donor_gain	1.0000
17:45034186:CCC:C	donor_gain	1.0000
17:45034186:CCCC:C	donor_gain	1.0000
17:45034186:CCCCG:C	donor_gain	1.0000
17:45034386:CACGA:C	acceptor_gain	1.0000
17:45034387:ACGA:A	acceptor_gain	1.0000
17:45034388:CGA:C	acceptor_gain	1.0000
17:45034388:CGAC:C	acceptor_gain	1.0000
17:45034389:GA:G	acceptor_gain	1.0000

AlphaMissense

3300 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:45086550:G:C	A95P	1.000
17:45086622:T:C	F119L	1.000
17:45086622:T:G	F119V	1.000
17:45086623:T:C	F119S	1.000
17:45086623:T:G	F119C	1.000
17:45086624:C:A	F119L	1.000
17:45086624:C:G	F119L	1.000
17:45086625:T:A	W120R	1.000
17:45086625:T:C	W120R	1.000
17:45086626:G:C	W120S	1.000
17:45086627:G:C	W120C	1.000
17:45086627:G:T	W120C	1.000
17:45086636:G:C	Q123H	1.000
17:45086636:G:T	Q123H	1.000
17:45086641:T:A	V125D	1.000
17:45093765:T:C	F156L	1.000
17:45093766:T:C	F156S	1.000
17:45093767:C:A	F156L	1.000
17:45093767:C:G	F156L	1.000
17:45093771:T:A	W158R	1.000
17:45093771:T:C	W158R	1.000
17:45093772:G:C	W158S	1.000
17:45093773:G:C	W158C	1.000
17:45093773:G:T	W158C	1.000
17:45096204:T:C	L172P	1.000
17:45096213:T:C	L175P	1.000
17:45096216:T:A	L176Q	1.000
17:45096216:T:C	L176P	1.000
17:45096226:C:A	N179K	1.000
17:45096226:C:G	N179K	1.000

dbSNP variants (sampled 300 via entrez): RS1000019596 (17:45083098 C>T), RS1000044869 (17:45090234 T>C), RS1000090905 (17:45085570 A>G), RS1000141883 (17:45066060 A>C,G), RS1000165309 (17:45100084 A>G), RS1000329032 (17:45106401 C>T), RS1000390616 (17:45083214 G>A), RS1000475446 (17:45099740 T>G), RS1000517927 (17:45067281 G>A,C), RS1000524224 (17:45069042 C>A), RS1000544875 (17:45109476 T>C), RS1000722861 (17:45072875 A>T), RS1000823635 (17:45079040 G>T), RS1001017632 (17:45094269 C>T), RS1001044217 (17:45091487 T>C)

Disease associations

OMIM: gene MIM:160993 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

18 associations (top):

Study	Trait	p-value
GCST004412_12	Craniofacial microsomia	9.000000e-06
GCST007267_237	Systolic blood pressure	1.000000e-14
GCST007269_305	Pulse pressure	1.000000e-13
GCST008512_36	Multisite chronic pain	2.000000e-09
GCST008916_39	Asthma	8.000000e-12
GCST010101_17	White matter hyperintensities	3.000000e-16
GCST010396_198	Gut microbiota (bacterial taxa, hurdle binary method)	3.000000e-06
GCST010661_9	Blood glucose levels	3.000000e-06
GCST010662_15	Systolic blood pressure	2.000000e-21
GCST010703_91	Brain morphology (MOSTest)	2.000000e-65
GCST010726_66	Periventricular white matter hyperintensities	9.000000e-09
GCST011122_24	Walking pace	3.000000e-09
GCST011947_2	White matter hyperintensity volume	3.000000e-19
GCST012332_3	Multisite chronic pain	1.000000e-09
GCST90002400_216	Plateletcrit	3.000000e-10
GCST90020026_436	Hip index	1.000000e-11
GCST90020026_437	Hip index	3.000000e-18
GCST90020028_1372	Hip circumference adjusted for BMI	3.000000e-11

EFO canonical traits (9, from GWAS)

EFO ID	Trait name
EFO:0006335	systolic blood pressure
EFO:0005763	pulse pressure measurement
EFO:0010100	multisite chronic pain
EFO:0005665	white matter hyperintensity measurement
EFO:0007874	gut microbiome measurement
EFO:0004468	glucose measurement
EFO:0004346	neuroimaging measurement
EFO:0007985	platelet crit
EFO:0008039	BMI-adjusted hip circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL2096973 (PROTEIN FAMILY), CHEMBL2593 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 21 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL3357685	ZELENIRSTAT	2	21

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — N-myristoyltransferases

Most potent curated ligand interactions (3 total), top 3:

Ligand	Action	Affinity	Parameter
zelenirstat	Inhibition	9.0	pIC50
MYX1715	Inhibition	8.82	pIC50
NMT inhibitor 1 [WO2024052685A1]	Inhibition	8.66	pIC50

Binding affinities (BindingDB)

207 measured of 233 human assays (233 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
N-[1,5-dimethyl-3-(2-methylpropyl)pyrazol-4-yl]-4-(2-methyl-1,3,4,5-tetrahydro-2-benzazepin-8-yl)benzenesulfonamide	IC50	2 nM	US-9156811: N-myristoyl transferase inhibitors
2,6-dichloro-4-(2-piperazin-1-yl-4-pyridinyl)-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	3 nM	US-9156811: N-myristoyl transferase inhibitors
2-chloro-4-(2-piperazin-1-yl-4-pyridinyl)-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	3 nM	US-9156811: N-myristoyl transferase inhibitors
2,6-dichloro-N-[1,5-dimethyl-3-(2-methylpropyl)pyrazol-4-yl]-4-(2-piperazin-1-yl-4-pyridinyl)benzenesulfonamide	IC50	3 nM	US-9156811: N-myristoyl transferase inhibitors
2,6-dichloro-N-ethyl-4-(2-piperazin-1-yl-4-pyridinyl)-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	3 nM	US-9156811: N-myristoyl transferase inhibitors
2,6-dichloro-N-methyl-4-(3-piperidin-4-ylpropyl)-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	4 nM	US-9156811: N-myristoyl transferase inhibitors
N-[1,5-dimethyl-3-(2-methylpropyl)pyrazol-4-yl]-4-(2,3,4,5-tetrahydro-1H-2-benzazepin-8-yl)benzenesulfonamide	IC50	4 nM	US-9156811: N-myristoyl transferase inhibitors
2,6-dichloro-N-(difluoromethyl)-4-(4-piperidin-4-ylbutyl)-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	4 nM	US-9156811: N-myristoyl transferase inhibitors
2,6-dichloro-N-methyl-4-(2-piperazin-1-yl-4-pyridinyl)-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	5 nM	US-9156811: N-myristoyl transferase inhibitors
4-[3-[(1-methylpiperidin-4-yl)methyl]phenyl]-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	5 nM	US-9156811: N-myristoyl transferase inhibitors
2,6-dichloro-N-methyl-4-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	5 nM	US-9156811: N-myristoyl transferase inhibitors
2,6-dichloro-N-(difluoromethyl)-4-[3-(1-methylpiperidin-4-yl)oxypropyl]-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	5 nM	US-9156811: N-myristoyl transferase inhibitors
2-methyl-4-(2-piperazin-1-yl-4-pyridinyl)-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	6 nM	US-9156811: N-myristoyl transferase inhibitors
2,6-dichloro-N-(difluoromethyl)-4-[4-(1-methylpiperidin-4-yl)butyl]-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	6 nM	US-9156811: N-myristoyl transferase inhibitors
N-[1,5-dimethyl-3-(2-methylpropyl)pyrazol-4-yl]-4-[3-[(2-pyridin-3-ylethylamino)methyl]phenyl]benzenesulfonamide	IC50	6 nM	US-9156811: N-myristoyl transferase inhibitors
4-(2-piperazin-1-yl-4-pyridinyl)-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	7 nM	US-9156811: N-myristoyl transferase inhibitors
2,6-dichloro-4-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	7 nM	US-9156811: N-myristoyl transferase inhibitors
2,6-dichloro-N-(difluoromethyl)-4-[3-(4-methyl-1,4-diazepan-1-yl)propyl]-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	7 nM	US-9156811: N-myristoyl transferase inhibitors
4-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	8 nM	US-9156811: N-myristoyl transferase inhibitors
4-[2-(3-methylpiperazin-1-yl)-4-pyridinyl]-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	8 nM	US-9156811: N-myristoyl transferase inhibitors
4-[2-(1,4-diazepan-1-yl)-4-pyridinyl]-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	8 nM	US-9156811: N-myristoyl transferase inhibitors
2,6-dichloro-4-(3-piperidin-4-ylpropyl)-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	8 nM	US-9156811: N-myristoyl transferase inhibitors
2,6-dichloro-4-[3-(1,4-diazepan-1-yl)propyl]-N-(difluoromethyl)-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	8 nM	US-9156811: N-myristoyl transferase inhibitors
2,6-dichloro-N-(1,5-dimethylpyrazol-4-yl)-4-(2-piperazin-1-yl-4-pyridinyl)benzenesulfonamide	IC50	9 nM	US-9156811: N-myristoyl transferase inhibitors
2-fluoro-4-(2-piperazin-1-yl-4-pyridinyl)-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	9 nM	US-9156811: N-myristoyl transferase inhibitors
N-methyl-4-[3-[(1-methylpiperidin-4-yl)methyl]phenyl]-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	9 nM	US-9156811: N-myristoyl transferase inhibitors
2,6-dichloro-N-ethyl-4-(3-piperidin-4-ylpropyl)-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	9 nM	US-9156811: N-myristoyl transferase inhibitors
2,6-dichloro-N-(difluoromethyl)-4-(3-piperidin-4-ylpropyl)-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	9 nM	US-9156811: N-myristoyl transferase inhibitors
2,6-dichloro-N-(1,3-dimethylpyrazol-4-yl)-4-(2-piperazin-1-yl-4-pyridinyl)benzenesulfonamide	IC50	10 nM	US-9156811: N-myristoyl transferase inhibitors
6-(3-piperazin-1-ylpiperidin-1-yl)-N-(1,3,5-trimethylpyrazol-4-yl)pyridine-3-sulfonamide	IC50	10 nM	US-9156811: N-myristoyl transferase inhibitors
2,6-dichloro-N-[1,5-dimethyl-3-(2-methylpropyl)pyrazol-4-yl]-4-(3-piperidin-4-ylpropyl)benzenesulfonamide	IC50	10 nM	US-9156811: N-myristoyl transferase inhibitors
4-[4-chloro-3-[(dimethylamino)methyl]phenyl]-N-[1,5-dimethyl-3-(2-methylpropyl)pyrazol-4-yl]benzenesulfonamide	IC50	10 nM	US-9156811: N-myristoyl transferase inhibitors
2,6-dichloro-4-[3-(1,4-diazepan-1-yl)propyl]-N-methyl-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	11 nM	US-9156811: N-myristoyl transferase inhibitors
4-[3-[(dimethylamino)methyl]-4-fluorophenyl]-N-[1,5-dimethyl-3-(2-methylpropyl)pyrazol-4-yl]benzenesulfonamide	IC50	11 nM	US-9156811: N-myristoyl transferase inhibitors
N-[1,5-dimethyl-3-(2-methylpropyl)pyrazol-4-yl]-4-(1,2,3,4-tetrahydroisoquinolin-7-yl)benzenesulfonamide	IC50	11 nM	US-9156811: N-myristoyl transferase inhibitors
N-(difluoromethyl)-4-(2-piperazin-1-yl-4-pyridinyl)-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	12 nM	US-9156811: N-myristoyl transferase inhibitors
2,5-difluoro-4-(2-piperazin-1-yl-4-pyridinyl)-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	13 nM	US-9156811: N-myristoyl transferase inhibitors
4-[3-[(dimethylamino)methyl]-4-methylphenyl]-N-[1,5-dimethyl-3-(2-methylpropyl)pyrazol-4-yl]benzenesulfonamide	IC50	13 nM	US-9156811: N-myristoyl transferase inhibitors
4-[3-[(dimethylamino)methyl]phenyl]-N-[1,5-dimethyl-3-(2-methylpropyl)pyrazol-4-yl]benzenesulfonamide	IC50	14 nM	US-9156811: N-myristoyl transferase inhibitors
4-[3-[(dimethylamino)methyl]phenyl]-N-[1,5-dimethyl-3-(2-methylpropyl)pyrazol-4-yl]benzenesulfonamide	IC50	15 nM	US-9156811: N-myristoyl transferase inhibitors
2,6-dichloro-4-(3-piperazin-1-ylphenyl)-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	16 nM	US-9156811: N-myristoyl transferase inhibitors
2,6-dichloro-N-[1,5-dimethyl-3-(2-methylpropyl)pyrazol-4-yl]-4-[3-(1-methylpiperidin-4-yl)propyl]benzenesulfonamide	IC50	16 nM	US-9156811: N-myristoyl transferase inhibitors
N-methyl-4-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	17 nM	US-9156811: N-myristoyl transferase inhibitors
4-[3-[(dimethylamino)methyl]phenyl]-N-[1,5-dimethyl-3-(2-methylpropyl)pyrazol-4-yl]-3-(trifluoromethyl)benzenesulfonamide	IC50	17 nM	US-9156811: N-myristoyl transferase inhibitors
4-[3-(1-azabicyclo[2.2.2]octan-3-yloxy)propyl]-2,6-dichloro-N-(difluoromethyl)-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	17 nM	US-9156811: N-myristoyl transferase inhibitors
2,6-dichloro-N-methyl-4-[3-(1-methylpiperidin-4-yl)propyl]-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	18 nM	US-9156811: N-myristoyl transferase inhibitors
4-[3-(2-aminopropan-2-yl)phenyl]-N-[1,5-dimethyl-3-(2-methylpropyl)pyrazol-4-yl]benzenesulfonamide	IC50	18 nM	US-9156811: N-myristoyl transferase inhibitors
2,6-dichloro-N-(difluoromethyl)-4-(2-piperazin-1-yl-4-pyridinyl)-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	18 nM	US-9156811: N-myristoyl transferase inhibitors
N-(2,2-difluoroethyl)-4-(2-piperazin-1-yl-4-pyridinyl)-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	IC50	19 nM	US-9156811: N-myristoyl transferase inhibitors
N-[1,5-dimethyl-3-(2-methylpropyl)pyrazol-4-yl]-4-[3-(methylaminomethyl)phenyl]benzenesulfonamide	IC50	19 nM	US-9156811: N-myristoyl transferase inhibitors

ChEMBL bioactivities

521 potent at pChembl≥5 of 627 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.41	IC50	0.39	nM	CHEMBL170807
9.40	IC50	0.4	nM	CHEMBL173370
9.24	IC50	0.58	nM	CHEMBL171506
9.15	IC50	0.71	nM	CHEMBL170524
9.05	Ki	0.9	nM	CHEMBL3357688
8.89	IC50	1.3	nM	CHEMBL422896
8.89	IC50	1.3	nM	CHEMBL355497
8.70	IC50	2	nM	CHEMBL422746
8.70	IC50	2	nM	CHEMBL4115136
8.52	IC50	3	nM	CHEMBL1230468
8.52	IC50	3	nM	CHEMBL4111551
8.52	IC50	3	nM	ZELENIRSTAT
8.52	IC50	3	nM	CHEMBL3980411
8.46	IC50	3.5	nM	CHEMBL355250
8.43	IC50	3.7	nM	CHEMBL158172
8.43	IC50	3.7	nM	CHEMBL155301
8.43	IC50	3.7	nM	CHEMBL347895
8.43	IC50	3.7	nM	CHEMBL155469
8.43	IC50	3.7	nM	CHEMBL345893
8.43	IC50	3.7	nM	CHEMBL347048
8.40	IC50	4	nM	ZELENIRSTAT
8.40	IC50	4	nM	CHEMBL3357697
8.40	IC50	4	nM	CHEMBL3357702
8.40	IC50	4	nM	CHEMBL3358119
8.40	IC50	4	nM	CHEMBL3920615
8.40	IC50	4	nM	CHEMBL4110040
8.40	IC50	4	nM	CHEMBL1230468
8.40	Ki	4	nM	CHEMBL1230468
8.32	Ki	4.8	nM	CHEMBL3770219
8.30	IC50	5	nM	CHEMBL3357699
8.30	IC50	5	nM	CHEMBL3358120
8.30	IC50	5	nM	CHEMBL3358121
8.30	IC50	5	nM	CHEMBL3357702
8.30	IC50	5	nM	CHEMBL4106967
8.30	IC50	5	nM	CHEMBL3911634
8.28	IC50	5.2	nM	CHEMBL158172
8.25	IC50	5.6	nM	CHEMBL347048
8.24	IC50	5.7	nM	CHEMBL347048
8.22	IC50	6	nM	CHEMBL4109103
8.22	IC50	6	nM	CHEMBL3358120
8.22	IC50	6	nM	CHEMBL4113504
8.21	Ki	6.2	nM	CHEMBL3357688
8.15	IC50	7	nM	CHEMBL4112331
8.15	IC50	7	nM	CHEMBL1951295
8.15	IC50	7	nM	CHEMBL3894086
8.12	IC50	7.5	nM	CHEMBL345893
8.10	IC50	8	nM	CHEMBL3357695
8.10	IC50	8	nM	CHEMBL3358122
8.10	IC50	8	nM	CHEMBL3357704
8.10	IC50	8	nM	CHEMBL4107350

PubChem BioAssay actives

310 with measured affinity, of 619 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(5-methyl-2-pyridinyl)-[3-methyl-4-[3-(pyridin-3-ylmethylamino)propoxy]-1-benzofuran-2-yl]methanone	143932: In vitro inhibitory activity against candida albicans Nmt (CaNmt) using substrate peptide GLTISKLFR-R-NH2 (0.5 uM) and myristoyl-CoA (0.5 uM)	ic50	0.0004	uM
(1-methylbenzimidazol-2-yl)-[3-methyl-4-[3-(pyridin-3-ylmethylamino)propoxy]-1-benzofuran-2-yl]methanone	143930: In vitro inhibitory activity against Candida albicans Nmt (CaNmt) using substrate peptide GLTISKLFR-R-NH2 (0.5 uM) and myristoyl-CoA (0.5 uM)	ic50	0.0004	uM
[3-methyl-4-[3-(pyridin-3-ylmethylamino)propoxy]-1-benzofuran-2-yl]-(1-prop-2-enylbenzimidazol-2-yl)methanone	143930: In vitro inhibitory activity against Candida albicans Nmt (CaNmt) using substrate peptide GLTISKLFR-R-NH2 (0.5 uM) and myristoyl-CoA (0.5 uM)	ic50	0.0006	uM
(4,5-dimethyl-1,3-thiazol-2-yl)-[3-methyl-4-[3-(pyridin-3-ylmethylamino)propoxy]-1-benzofuran-2-yl]methanone	143930: In vitro inhibitory activity against Candida albicans Nmt (CaNmt) using substrate peptide GLTISKLFR-R-NH2 (0.5 uM) and myristoyl-CoA (0.5 uM)	ic50	0.0007	uM
2,6-dichloro-4-[2-(4-methylpiperazin-1-yl)-4-pyridinyl]-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	1545668: Inhibition of human NMT1 L495M mutant expressed in Escherichia coli Rosetta-2 cells using GSNKSKPK as substrate in presence of MyrCoA after 30 mins by CPM dye based fluorescence assay	ki	0.0009	uM
1-[5-[3,4-difluoro-2-[2-(1,3,5-trimethylpyrazol-4-yl)ethoxy]phenyl]-1-methylindazol-3-yl]-N,N-dimethylmethanamine	1582663: Inhibition of human N-myristoyltransferase assessed as reduction in CoASH production by fluorogenic detection based assay	ic50	0.0010	uM
(1-methylimidazol-2-yl)-[3-methyl-4-[3-(pyridin-3-ylmethylamino)propoxy]-1-benzofuran-2-yl]methanone	143930: In vitro inhibitory activity against Candida albicans Nmt (CaNmt) using substrate peptide GLTISKLFR-R-NH2 (0.5 uM) and myristoyl-CoA (0.5 uM)	ic50	0.0013	uM
[3-methyl-4-[3-(pyridin-3-ylmethylamino)propoxy]-1-benzofuran-2-yl]-(1-propan-2-ylbenzimidazol-2-yl)methanone	143930: In vitro inhibitory activity against Candida albicans Nmt (CaNmt) using substrate peptide GLTISKLFR-R-NH2 (0.5 uM) and myristoyl-CoA (0.5 uM)	ic50	0.0013	uM
[3-methyl-4-[3-(pyridin-3-ylmethylamino)propoxy]-1-benzofuran-2-yl]-(4-methyl-1,3-thiazol-2-yl)methanone	143930: In vitro inhibitory activity against Candida albicans Nmt (CaNmt) using substrate peptide GLTISKLFR-R-NH2 (0.5 uM) and myristoyl-CoA (0.5 uM)	ic50	0.0020	uM
2,6-dichloro-4-(2-piperazin-1-yl-4-pyridinyl)-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	1171505: Inhibition of human N-myristoyltransferase 1 assessed as transfer of [3H]-myristic acid to a biotinylated substrate peptide (GCGGSKVKPQPPQAK(biotin)-amide by scintillation proximity assay	ic50	0.0030	uM
[3-methyl-4-[3-(pyridin-3-ylmethylamino)propoxy]-1-benzofuran-2-yl]-pyridin-2-ylmethanone	143923: In vitro inhibitory activity against Candida albicans Nmt (CaNmt) using substrate peptide GLTISKLFR-R-NH2 (0.5 uM) and myristoyl-CoA (0.5 uM)	ic50	0.0035	uM
3-[[2-[(2-fluorophenoxy)methyl]-3-methyl-1-benzofuran-4-yl]oxy]-N-(pyridin-3-ylmethyl)propan-1-amine	143884: Inhibitory activity against Candida albicans (Nmt) assessed as inhibitory concentration	ic50	0.0037	uM
3-[[2-[(4-fluorophenoxy)methyl]-3-methyl-1-benzofuran-4-yl]oxy]-N-(pyridin-3-ylmethyl)propan-1-amine	143885: Inhibitory activity against Candida albicans (Nmt) assessed as inhibitory concentration (nM)	ic50	0.0037	uM
3-[[2-[(2,3-difluorophenoxy)methyl]-3-methyl-1-benzofuran-4-yl]oxy]-N-(pyridin-3-ylmethyl)propan-1-amine	143885: Inhibitory activity against Candida albicans (Nmt) assessed as inhibitory concentration (nM)	ic50	0.0037	uM
3-[[2-[(2,4-difluorophenoxy)methyl]-3-methyl-1-benzofuran-4-yl]oxy]-N-(pyridin-3-ylmethyl)propan-1-amine	143885: Inhibitory activity against Candida albicans (Nmt) assessed as inhibitory concentration (nM)	ic50	0.0037	uM
3-[[3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]-1-benzofuran-4-yl]oxy]-N-(pyridin-3-ylmethyl)propan-1-amine	143886: Inhibitory activity against Candida albicans (Nmt) assessed as inhibitory concentration (nM); 3.7-9.4 nM	ic50	0.0037	uM
4-[[3-methyl-4-[3-(pyridin-3-ylmethylamino)propoxy]-1-benzofuran-2-yl]methoxy]benzonitrile	143889: Inhibitory activity against Candida albicans N-Myristoyltransferase (Nmt)	ic50	0.0037	uM
2,6-dichloro-4-[4-(1-methylpiperidin-4-yl)butyl]-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	1171505: Inhibition of human N-myristoyltransferase 1 assessed as transfer of [3H]-myristic acid to a biotinylated substrate peptide (GCGGSKVKPQPPQAK(biotin)-amide by scintillation proximity assay	ic50	0.0040	uM
2,6-dichloro-N-(difluoromethyl)-4-(4-piperidin-4-ylbutyl)-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	1171505: Inhibition of human N-myristoyltransferase 1 assessed as transfer of [3H]-myristic acid to a biotinylated substrate peptide (GCGGSKVKPQPPQAK(biotin)-amide by scintillation proximity assay	ic50	0.0040	uM
2,6-dichloro-N-methyl-4-(2-piperazin-1-yl-4-pyridinyl)-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	1171505: Inhibition of human N-myristoyltransferase 1 assessed as transfer of [3H]-myristic acid to a biotinylated substrate peptide (GCGGSKVKPQPPQAK(biotin)-amide by scintillation proximity assay	ic50	0.0040	uM
2,6-dichloro-N-[1,5-dimethyl-3-(2-methylpropyl)pyrazol-4-yl]-4-(2-piperazin-1-yl-4-pyridinyl)benzenesulfonamide	1171505: Inhibition of human N-myristoyltransferase 1 assessed as transfer of [3H]-myristic acid to a biotinylated substrate peptide (GCGGSKVKPQPPQAK(biotin)-amide by scintillation proximity assay	ic50	0.0040	uM
2-(5-chloro-2-piperidin-4-yloxyphenyl)-5-[(1,3,5-trimethylpyrazol-4-yl)methyl]-1,3,4-oxadiazole	1545670: Inhibition of human NMT1 R295Q/W297F/A452M/L453V/L462V/N473H/L495M/Q496L mutant expressed in Escherichia coli Rosetta-2 cells using GSNKSKPK as substrate in presence of MyrCoA after 30 mins by CPM dye based fluorescence assay	ki	0.0048	uM
2,6-dichloro-4-(4-piperidin-4-ylbutyl)-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	1171505: Inhibition of human N-myristoyltransferase 1 assessed as transfer of [3H]-myristic acid to a biotinylated substrate peptide (GCGGSKVKPQPPQAK(biotin)-amide by scintillation proximity assay	ic50	0.0050	uM
2,6-dichloro-N-(difluoromethyl)-4-[3-(1-methylpiperidin-4-yl)oxypropyl]-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	1171505: Inhibition of human N-myristoyltransferase 1 assessed as transfer of [3H]-myristic acid to a biotinylated substrate peptide (GCGGSKVKPQPPQAK(biotin)-amide by scintillation proximity assay	ic50	0.0050	uM
2,6-dichloro-N-(difluoromethyl)-4-[4-(1-methylpiperidin-4-yl)butyl]-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	1171505: Inhibition of human N-myristoyltransferase 1 assessed as transfer of [3H]-myristic acid to a biotinylated substrate peptide (GCGGSKVKPQPPQAK(biotin)-amide by scintillation proximity assay	ic50	0.0050	uM
2,6-dichloro-4-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	646358: Inhibition of human N-myristoyltransferase 1 using [3H]myristoyl-CoA and GCGGSKVKPQPPQAK(biotin)-amide as substrate preincubated for 5 mins prior substrate addition measured after 50 mins by streptavidin-coated scintillation proximity assay	ic50	0.0070	uM
2,6-dichloro-N-(difluoromethyl)-4-[6-(dimethylamino)hexyl]-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	1171505: Inhibition of human N-myristoyltransferase 1 assessed as transfer of [3H]-myristic acid to a biotinylated substrate peptide (GCGGSKVKPQPPQAK(biotin)-amide by scintillation proximity assay	ic50	0.0080	uM
ethyl 6-[[6-(3-aminopropylamino)-3-pyridinyl]methoxy]-4-ethylsulfanylquinoline-3-carboxylate	1506565: Inhibition of N-terminal deletion human NMT1 expressed in Escherichia coli BL21 (DE3) using Hs pp60src (2 to 9 residues) as substrate measured every min for 30 mins by CPM-based fluorescence assay	ki	0.0080	uM
2,6-dichloro-4-(3-piperidin-4-ylpropyl)-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	1171505: Inhibition of human N-myristoyltransferase 1 assessed as transfer of [3H]-myristic acid to a biotinylated substrate peptide (GCGGSKVKPQPPQAK(biotin)-amide by scintillation proximity assay	ic50	0.0080	uM
4-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	1171505: Inhibition of human N-myristoyltransferase 1 assessed as transfer of [3H]-myristic acid to a biotinylated substrate peptide (GCGGSKVKPQPPQAK(biotin)-amide by scintillation proximity assay	ic50	0.0090	uM
2,6-dichloro-N-(difluoromethyl)-4-(3-piperidin-4-ylpropyl)-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	1171505: Inhibition of human N-myristoyltransferase 1 assessed as transfer of [3H]-myristic acid to a biotinylated substrate peptide (GCGGSKVKPQPPQAK(biotin)-amide by scintillation proximity assay	ic50	0.0090	uM
2,6-dichloro-N-(1,5-dimethylpyrazol-4-yl)-4-(2-piperazin-1-yl-4-pyridinyl)benzenesulfonamide	1171505: Inhibition of human N-myristoyltransferase 1 assessed as transfer of [3H]-myristic acid to a biotinylated substrate peptide (GCGGSKVKPQPPQAK(biotin)-amide by scintillation proximity assay	ic50	0.0090	uM
1-[4-[2,5-difluoro-4-[(2-methyl-3-pyridinyl)methoxy]phenyl]-2-pyridinyl]piperazine	1477251: Inhibition of human NMT1 using [3H]-myristoyl-coA/biotinylated CAP5.5 as substrate after 15 mins by scintillation/luminescence counting method	ic50	0.0100	uM
2,6-dichloro-N-(difluoromethyl)-4-[3-(1-methylpiperidin-4-yl)propyl]-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	1171505: Inhibition of human N-myristoyltransferase 1 assessed as transfer of [3H]-myristic acid to a biotinylated substrate peptide (GCGGSKVKPQPPQAK(biotin)-amide by scintillation proximity assay	ic50	0.0120	uM
2,6-dichloro-N-(1,3-dimethylpyrazol-4-yl)-4-(2-piperazin-1-yl-4-pyridinyl)benzenesulfonamide	1171505: Inhibition of human N-myristoyltransferase 1 assessed as transfer of [3H]-myristic acid to a biotinylated substrate peptide (GCGGSKVKPQPPQAK(biotin)-amide by scintillation proximity assay	ic50	0.0120	uM
N-[[2-(1-methylazepan-4-yl)-3-pyridinyl]methyl]-2-(5-methylimidazol-1-yl)propanamide	1545670: Inhibition of human NMT1 R295Q/W297F/A452M/L453V/L462V/N473H/L495M/Q496L mutant expressed in Escherichia coli Rosetta-2 cells using GSNKSKPK as substrate in presence of MyrCoA after 30 mins by CPM dye based fluorescence assay	ki	0.0145	uM
4-[1-(2-methoxyphenyl)pyrazol-4-yl]-N-[2-(1-methylpyrrolidin-2-yl)ethyl]pyrimidin-2-amine	1545670: Inhibition of human NMT1 R295Q/W297F/A452M/L453V/L462V/N473H/L495M/Q496L mutant expressed in Escherichia coli Rosetta-2 cells using GSNKSKPK as substrate in presence of MyrCoA after 30 mins by CPM dye based fluorescence assay	ki	0.0167	uM
2-[[3-methyl-4-[3-(pyridin-3-ylmethylamino)propoxy]-1-benzofuran-2-yl]methoxy]benzonitrile	143887: Inhibitory activity against Candida albicans N-Myristoyltransferase (CaNmt) assessed as inhibitory concentration using substrate peptide and myristotyl-CoA at 0.5 uM	ic50	0.0170	uM
N-methyl-4-[3-[(4-methylpiperazin-1-yl)methyl]phenyl]-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	1171505: Inhibition of human N-myristoyltransferase 1 assessed as transfer of [3H]-myristic acid to a biotinylated substrate peptide (GCGGSKVKPQPPQAK(biotin)-amide by scintillation proximity assay	ic50	0.0170	uM
2,6-dichloro-4-(3-piperazin-1-ylphenyl)-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	1171505: Inhibition of human N-myristoyltransferase 1 assessed as transfer of [3H]-myristic acid to a biotinylated substrate peptide (GCGGSKVKPQPPQAK(biotin)-amide by scintillation proximity assay	ic50	0.0170	uM
4-[3-[(8aR)-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazin-2-yl]propyl]-2,6-dichloro-N-methyl-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	1545668: Inhibition of human NMT1 L495M mutant expressed in Escherichia coli Rosetta-2 cells using GSNKSKPK as substrate in presence of MyrCoA after 30 mins by CPM dye based fluorescence assay	ki	0.0180	uM
2,6-dichloro-N-methyl-4-[3-(1-methylpiperidin-4-yl)propyl]-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	1171505: Inhibition of human N-myristoyltransferase 1 assessed as transfer of [3H]-myristic acid to a biotinylated substrate peptide (GCGGSKVKPQPPQAK(biotin)-amide by scintillation proximity assay	ic50	0.0180	uM
2,6-dichloro-N-methyl-4-(3-piperazin-1-ylpropyl)-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	1545668: Inhibition of human NMT1 L495M mutant expressed in Escherichia coli Rosetta-2 cells using GSNKSKPK as substrate in presence of MyrCoA after 30 mins by CPM dye based fluorescence assay	ki	0.0191	uM
(2S)-6-amino-N-(2-cyclohexylethyl)-2-[[(2S)-3-hydroxy-2-[[(2R)-2-[4-[4-(2-methylimidazol-1-yl)butyl]phenyl]propanoyl]amino]propanoyl]amino]hexanamide	143938: Inhibition activity against N-myristoyltransferase (NMT) of candida albicans.	ic50	0.0200	uM
N-methyl-4-(2-piperazin-1-yl-4-pyridinyl)-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	1171505: Inhibition of human N-myristoyltransferase 1 assessed as transfer of [3H]-myristic acid to a biotinylated substrate peptide (GCGGSKVKPQPPQAK(biotin)-amide by scintillation proximity assay	ic50	0.0220	uM
2,6-dichloro-4-(3-piperidin-4-ylphenyl)-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	1171505: Inhibition of human N-myristoyltransferase 1 assessed as transfer of [3H]-myristic acid to a biotinylated substrate peptide (GCGGSKVKPQPPQAK(biotin)-amide by scintillation proximity assay	ic50	0.0230	uM
4-[1-(3-methoxyphenyl)pyrazol-4-yl]-N-[2-(1-methylpyrrolidin-2-yl)ethyl]pyrimidin-2-amine	1545670: Inhibition of human NMT1 R295Q/W297F/A452M/L453V/L462V/N473H/L495M/Q496L mutant expressed in Escherichia coli Rosetta-2 cells using GSNKSKPK as substrate in presence of MyrCoA after 30 mins by CPM dye based fluorescence assay	ki	0.0238	uM
5-(2-piperidin-4-yloxy-3-pyridinyl)-3-(quinolin-5-ylmethyl)-1,2,4-oxadiazole	1270572: Inhibition of human NMT1 by 7-diethylamine-3-(4’maleimidylphenyl)-4-methylcoumarin based fluorescence assay	ki	0.0240	uM
2,6-dichloro-N-ethyl-4-[3-(1-methylpiperidin-4-yl)propyl]-N-(1,3,5-trimethylpyrazol-4-yl)benzenesulfonamide	1171505: Inhibition of human N-myristoyltransferase 1 assessed as transfer of [3H]-myristic acid to a biotinylated substrate peptide (GCGGSKVKPQPPQAK(biotin)-amide by scintillation proximity assay	ic50	0.0240	uM
2,6-dichloro-N-[1,3-dimethyl-5-(2-methylpropyl)pyrazol-4-yl]-4-(2-piperazin-1-yl-4-pyridinyl)benzenesulfonamide	1171505: Inhibition of human N-myristoyltransferase 1 assessed as transfer of [3H]-myristic acid to a biotinylated substrate peptide (GCGGSKVKPQPPQAK(biotin)-amide by scintillation proximity assay	ic50	0.0250	uM

CTD chemical–gene interactions

50 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	decreases expression, affects cotreatment	3
sodium arsenite	affects binding, decreases reaction, decreases expression, increases activity, increases expression	2
aristolochic acid I	increases expression	1
FR900359	affects phosphorylation	1
bisphenol F	increases expression	1
bufotalin	increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects cotreatment, increases expression	1
beta-lapachone	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
benzo(e)pyrene	decreases methylation, increases methylation	1
cadmium acetate	decreases expression	1
aflatoxin B2	decreases methylation	1
di-n-butylphosphoric acid	affects expression	1
2,3,5-(triglutathion-S-yl)hydroquinone	decreases ADP-ribosylation	1
cylindrospermopsin	increases expression	1
CGP 52608	affects binding, increases reaction	1
desloratadine	affects binding, decreases activity, affects response to substance	1
monomethylarsonous acid	increases expression	1
K 7174	decreases expression	1
bisphenol B	increases expression	1
N’-((2-hydroxyphenyl)carbonothioyl)pyridine-2-carbohydrazide	affects binding, decreases activity	1
bisphenol S	decreases methylation	1
bisphenol AF	increases expression	1
Arsenic Trioxide	increases expression	1
Acetaminophen	decreases expression	1
Benzo(a)pyrene	affects methylation	1
Caffeine	increases phosphorylation	1
Copper	affects binding, decreases activity	1
Coumestrol	increases expression	1

ChEMBL screening assays

93 unique, capped per target: 75 binding, 18 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL744115	Binding	Tested for Inhibitory concentration against human N-myristoyltransferase (NMT) in radiochemical HPLC end point assay with peptide GNAASARR-NH2 and [3H]myristoyl-CoA radioligand at 1 uM	Replacements for lysine in l-seryl-l-lysyl dipeptide amide inhibitors of candida albicans myristoyl-CoA:protein N-myristoyltransferase — Bioorg Med Chem Lett
CHEMBL4236878	ADMET	Inhibition of human NMT1 using [3H]-myristoyl-coA/biotinylated CAP5.5 as substrate after 15 mins by scintillation proximity assay	A Molecular Hybridization Approach for the Design of Potent, Highly Selective, and Brain-Penetrant N-Myristoyltransferase Inhibitors. — J Med Chem

Cellosaurus cell lines

8 cell lines: 7 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D1P8	Abcam K-562 NMT1 KO	Cancer cell line	Female
CVCL_D2KU	Abcam Raji NMT1 KO	Cancer cell line	Male
CVCL_D9LD	Ubigene HEK293 NMT1 KO	Transformed cell line	Female
CVCL_TA80	HAP1 NMT1 (-) 1	Cancer cell line	Male
CVCL_TA81	HAP1 NMT1 (-) 2	Cancer cell line	Male
CVCL_TA82	HAP1 NMT1 (-) 3	Cancer cell line	Male
CVCL_TA83	HAP1 NMT1 (-) 4	Cancer cell line	Male
CVCL_WQ11	Abcam Jurkat NMT1 KO	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.